MedPath

Inetetamab

Generic Name
Inetetamab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

Inetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

Indication

本品用于HER2阳性的转移性乳腺癌。与长春瑞宾联合治疗接受过1个或多个化疗方案的转移性乳腺癌患者。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Phase 2
Conditions
Metastatic Breast Cancer
Interventions
Drug: Pyrotinib
Drug: Vinorelbine
Drug: Inetetamab
First Posted Date
2021-07-15
Last Posted Date
2021-07-15
Lead Sponsor
Zhiyong Yu
Target Recruit Count
100
Registration Number
NCT04963595

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Phase 3
Not yet recruiting
Conditions
Breast Cancer
Interventions
Drug: Pyrotinib
Drug: Inetetamab
Drug: Rapamycin
Drug: Chemotherapy
First Posted Date
2021-02-03
Last Posted Date
2021-02-03
Lead Sponsor
Peking Union Medical College
Target Recruit Count
270
Registration Number
NCT04736589
Locations
🇨🇳

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

First Posted Date
2020-12-23
Last Posted Date
2020-12-23
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
71
Registration Number
NCT04681911
Locations
🇨🇳

Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy